The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
BAP1 mutations in high-grade meningioma: implications for patient care
Open accessAbstract
We have recently shown that the breast cancer (BRCA)1-associated protein-1 tumor suppressor gene (BAP1) is inactivated in a subset of clinically aggressive meningiomas that display rhabdoid histomorphology. Immunohistochemistry for BAP1 protein provides a rapid and inexpensive method for screening suspected cases. Notably, some patients with BAP1-mutant meningiomas have germline BAP1 mutations and BAP1 tumor predisposition syndrome (TPDS). It appears that nearly all patients with germline BAP1 mutations develop malignancies by age 55, most frequently uveal melanoma, cutaneous melanoma, pleural or peritoneal malignant mesothelioma, or renal cell carcinoma, although other cancers have also been associated with BAP1 TPDS. Therefore, when confronted with a patient with a potentially high-grade rhabdoid meningioma, it is important that neuropathologists assess the BAP1 status of the tumor and that the patient's family history of cancer is carefully ascertained. In the appropriate clinical setting, genetic counseling and germline BAP1 DNA sequencing should be performed. A cancer surveillance program for individuals who carry germline BAP1 mutations may help identify tumors such as uveal melanoma, cutaneous melanoma, and renal cell carcinoma at early and treatable stages. Because BAP1-mutant meningiomas are rare tumors, multi-institutional efforts will be needed to evaluate therapeutic strategies and to further define the clinicopathologic features of these tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Bott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma
Xu, J., Kadariya, Y., Cheung, M., Pei, J., Talarchek, J., Sementino, E., Tan, Y., Menges, C. W., Cai, K. Q., Litwin, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1328 · Cited by 144
Research works printed but not linked: 87
- 2017, Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas, Neuro Oncol, 19, 535
- 2017, SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas, Neuro Oncol, 19, 345
- 2013, Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations, Nat Genet, 45, 285, 10.1038/ng.2526 · DOI · Paper page
- 2013, Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO, Science, 339, 1077, 10.1126/science.1233009 · DOI · Paper page
- 2016, Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas, Nat Genet, 48, 1253, 10.1038/ng.3651 · DOI · Paper page
- 2016, Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma, Neuro Oncol, 18, 649, 10.1093/neuonc/nov316 · DOI · Paper page
- 2013, Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations, Acta Neuropathol, 125, 351, 10.1007/s00401-013-1093-x · DOI · Paper page
- 2014, Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5, Oncotarget, 5, 10596, 10.18632/oncotarget.2517 · DOI
- 2017, Integrated genomic analyses of de novo pathways underlying atypical meningiomas, Nat Commun, 8, 14433, 10.1038/ncomms14433 · DOI · Paper page
- 2002, A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas, Brain Pathol, 12, 183, 10.1111/j.1750-3639.2002.tb00433.x · doi:10.1111/j.1750-3639.2002.tb00433.x
- 2015, ARID1A and TERT promoter mutations in dedifferentiated meningioma, Cancer Genet, 208, 345, 10.1016/j.cancergen.2015.03.005 · DOI
- 2014, High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression, Brain Pathol, 24, 184, 10.1111/bpa.12110 · DOI · Paper page
- 2016, TERT promoter mutations and risk of recurrence in meningioma, J Natl Cancer Inst, 108
- 2016, Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539, Neuro Oncol, 18, 565, 10.1093/neuonc/nov247 · DOI
- 2016, A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma, Neuro Oncol, 18, 269, 10.1093/neuonc/nov177 · DOI
- 2015, Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds, Neuro Oncol, 17, 663, 10.1093/neuonc/nov002 · doi:10.1093/neuonc/nov002
- 2017, Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community, Neuro Oncol, 19, 336
- 2016, Predicting outcome of epilepsy after meningioma resection, Neuro Oncol, 18, 1002, 10.1093/neuonc/nov303 · DOI
- 2016, Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade, Neuro Oncol, 18, 863, 10.1093/neuonc/nov285 · DOI
- 2016, Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma, Neuro Oncol, 18, 401, 10.1093/neuonc/nov183 · doi:10.1093/neuonc/nov183
- 2015, Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma, Neuro Oncol, 17, 116, 10.1093/neuonc/nou148 · DOI · Paper page
- 1993, Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus, Hum Mol Genet, 2, 1215, 10.1093/hmg/2.8.1215 · doi:10.1093/hmg/2.8.1215
- 2014, Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas, J Pathol, 234, 436, 10.1002/path.4427 · doi:10.1002/path.4427
- 2013, Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas, Nat Genet, 45, 295, 10.1038/ng.2552 · DOI · Paper page
- 2011, Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas, J Med Genet, 48, 93, 10.1136/jmg.2010.082420 · DOI
- 2010, Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation, Neurogenetics, 11, 73, 10.1007/s10048-009-0204-2 · doi:10.1007/s10048-009-0204-2
- 2011, Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers, J Med Genet, 48, 856, 10.1136/jmedgenet-2011-100156 · DOI · Paper page
- 2015, Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction, Cancer Lett, 369, 261, 10.1016/j.canlet.2015.09.011 · DOI
- 2015, A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma, Clin Genet, 88, 267, 10.1111/cge.12501 · DOI
- 2015, Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States, Neuro Oncol, 17, 1166, 10.1093/neuonc/nov069 · doi:10.1093/neuonc/nov069
- 2016, Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010, Neuro Oncol
- 1998, “Rhabdoid” meningioma: an aggressive variant, Am J Surg Pathol, 22, 1482, 10.1097/00000478-199812000-00005 · doi:10.1097/00000478-199812000-00005
- 2016, Meningiomas with rhabdoid features lacking other histologic features of malignancy: a study of 44 cases and review of the literature, J Neuropathol Exp Neurol, 75, 44, 10.1093/jnen/nlv006 · DOI
- 2016, Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat Genet, 48, 407, 10.1038/ng.3520 · DOI · Paper page
- 2010, Frequent mutation of BAP1 in metastasizing uveal melanomas, Science, 330, 1410, 10.1126/science.1194472 · DOI · Paper page
- 2011, Germline BAP1 mutations predispose to malignant mesothelioma, Nat Genet, 43, 1022, 10.1038/ng.912 · DOI · Paper page
- 2015, Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases, Lung Cancer, 87, 77, 10.1016/j.lungcan.2014.10.017 · DOI
- 2016, Gender-specific molecular and clinical features underlie malignant pleural mesothelioma, Cancer Res, 76, 319, 10.1158/0008-5472.CAN-15-0751 · DOI
- 2014, Recent developments in prognostic and predictive testing in uveal melanoma, Curr Opin Ophthalmol, 25, 234, 10.1097/ICU.0000000000000051 · DOI · Paper page
- 2012, Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families, PLoS One, 7, e35295, 10.1371/journal.pone.0035295 · DOI · Paper page
- 2013, A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers, PLoS One, 8, e72144, 10.1371/journal.pone.0072144 · DOI
- 2015, Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival, Carcinogenesis, 36, 76, 10.1093/carcin/bgu227 · DOI · Paper page
- 2016, Consensus report of the 2015 Weinman International Conference on Mesothelioma, J Thorac Oncol, 11, 1246, 10.1016/j.jtho.2016.04.028 · DOI
- 2013, Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations, J Thorac Oncol, 8, 1430, 10.1097/JTO.0b013e31829e7ef9 · DOI
- 2016, The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma, Mod Pathol, 29, 14, 10.1038/modpathol.2015.121 · DOI
- 2009, Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi, Nature, 457, 599, 10.1038/nature07586 · DOI · Paper page
- 2010, Mutations in GNA11 in uveal melanoma, N Engl J Med, 363, 2191, 10.1056/NEJMoa1000584 · DOI · Paper page
- 2016, Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes, JAMA Ophthalmol, 134, 728, 10.1001/jamaophthalmol.2016.0903 · DOI · Paper page
- 2015, Loss of BAP1 function leads to EZH2-dependent transformation, Nat Med, 21, 1344, 10.1038/nm.3947 · DOI · Paper page
- 2017, DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis, Lancet Oncol
- 2017, Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma, Acta Neuropathol, 133, 431, 10.1007/s00401-017-1678-x · DOI · Paper page
- 2015, High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma, J Thorac Oncol, 10, 565, 10.1097/JTO.0000000000000471 · DOI · Paper page
- 2016, Comparing the prognostic value of BAP1 mutation pattern, chromosome 3 status, and BAP1 immunohistochemistry in uveal melanoma, Am J Surg Pathol, 40, 796, 10.1097/PAS.0000000000000645 · DOI
- 2013, Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC, Epigenetics, 8, 486, 10.4161/epi.24552 · DOI
- 2017, Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy, Neuro Oncol, 19, 699
- 2017, Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors, Neuro Oncol
- 2014, Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma, Mod Pathol, 27, 1321, 10.1038/modpathol.2014.43 · DOI · Paper page
- 2015, Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s, PLoS Genet, 11, e1005633, 10.1371/journal.pgen.1005633 · DOI
- 2013, Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma, Cancer Genet, 206, 206, 10.1016/j.cancergen.2013.05.018 · DOI
- 2012, Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations, J Clin Oncol, 30, e337, 10.1200/JCO.2011.41.2965 · DOI
- 2012, A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression, Am J Surg Pathol, 36, 818, 10.1097/PAS.0b013e3182498be5 · DOI · Paper page
- 2012, BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs, J Transl Med, 10, 179, 10.1186/1479-5876-10-179 · DOI · Paper page
- 2015, Analysis of BAP1 germline gene mutation in young uveal melanoma patients, Ophthalmic Genet, 36, 126, 10.3109/13816810.2015.1010734 · DOI
- 2012, A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma, Pigment Cell Melanoma Res, 25, 815, 10.1111/pcmr.12006 · DOI
- 2014, Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O, Mol Cell, 54, 392, 10.1016/j.molcel.2014.03.002 · DOI · Paper page
- 2012, Loss of the tumor suppressor BAP1 causes myeloid transformation, Science, 337, 1541, 10.1126/science.1221711 · DOI · Paper page
- 2002, Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains, EMBO J, 21, 6755, 10.1093/emboj/cdf691 · DOI · Paper page
- 2009, Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia, Br J Haematol, 145, 788, 10.1111/j.1365-2141.2009.07697.x · DOI · Paper page
- 2016, Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations, Cancer Res, 76, 2836, 10.1158/0008-5472.CAN-15-3371 · DOI
- 2016, Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma, Oncogene, 35, 1996, 10.1038/onc.2015.243 · DOI · Paper page
- 2012, Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma, Cancer Sci, 103, 868, 10.1111/j.1349-7006.2012.02223.x · DOI · Paper page
- 2015, BAP1 missense mutation c.2054 A>T (p.E685V) completely disrupts normal splicing through creation of a novel 5ʹ splice site in a human mesothelioma cell line, PLoS One, 10, e0119224, 10.1371/journal.pone.0119224 · DOI
- 2015, Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells, Cancer Sci, 106, 990, 10.1111/cas.12698 · DOI
- 2016, A tumor-specific neo-antigen caused by a frameshift mutation in BAP1 is a potential personalized biomarker in malignant peritoneal mesothelioma, Int J Mol Sci, 17
- 2012, Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma, Clin Cancer Res, 18, 408, 10.1158/1078-0432.CCR-11-0946 · DOI · Paper page
- 2015, Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial, Lancet Oncol, 16, 447, 10.1016/S1470-2045(15)70056-2 · DOI · Paper page
- 2014, Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial, JAMA, 311, 2397, 10.1001/jama.2014.6096 · DOI · Paper page
- 2016, Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status, Nat Med, 22, 577, 10.1038/nm.4098 · DOI
- 2016, Reply to “Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status”, Nat Med, 22, 578, 10.1038/nm.4094 · DOI
- 2014, Germline mutations in BAP1 impair its function in DNA double-strand break repair, Cancer Res, 74, 4282, 10.1158/0008-5472.CAN-13-3109 · DOI · Paper page
- 2012, BAP1 loss defines a new class of renal cell carcinoma, Nat Genet, 44, 751, 10.1038/ng.2323 · DOI · Paper page
- 2016, Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases, Clin Genet, 89, 285, 10.1111/cge.12630 · DOI · Paper page
- 2015, Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations, JAMA Ophthalmol, 133, 881, 10.1001/jamaophthalmol.2015.1119 · DOI
- 2016, BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study, J Thorac Oncol, 11, 2006, 10.1016/j.jtho.2016.06.020 · DOI
- 2017, A population-based analysis of germline BAP1 mutations in melanoma, Hum Mol Genet
- 2011, Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma, Nat Genet, 44, 17, 10.1038/ng.1014 · DOI · Paper page
- 2013, Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas, Nat Genet, 45, 1470, 10.1038/ng.2813 · DOI · Paper page
Cited by
Gritsch, S., Batchelor, T. T., & Gonzalez Castro, L. N. (2022) · Cancer · doi:10.1002/cncr.33918 · Cited by 372
Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions
Ogasawara, C., Philbrick, B. D., & Adamson, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9030319 · Cited by 324
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1220 · Cited by 287
Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities
Choudhury, A., Magill, S. T., Eaton, C. D., Prager, B. C., Chen, W. C., Cady, M. A., Seo, K., Lucas, C.-H. G., Casey-Clyde, T. J., Vasudevan, H. N., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01061-8 · Cited by 293
How Asbestos and Other Fibers Cause Mesothelioma
Gaudino, G., Xue, J., & Yang, H. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.02.01 · Cited by 102
Metadata
- Authors
- Shankar, G. M., & Santagata, S.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-05-08
- Volume
- 19
- Issue
- 11
- Pages
- 1447-1456
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2612865792
- Cited by
- 174
- References
- 3
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BAP1 mutations in high-grade meningioma: implications for patient care. https://app.cochat.ai/papers/10.1093/neuonc/nox094
- The paper
- Shankar, G. M., & Santagata, S. (2017). BAP1 mutations in high-grade meningioma: implications for patient care. Neuro-Oncology. https://doi.org/10.1093/neuonc/nox094
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.